NYXH Stock Analysis — NYXOAH (Healthcare >> Medical Instruments & Supplies)
NYXH FAQ
What is NYXH's ROE?
NYXOAH reports a Return on Equity (ROE) of -239.18%.
What is NYXH's dividend yield?
NYXOAH offers a dividend yield of 0.00%.
What is NYXH's Quality Score?
Our AI rates NYXH's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NYXH?
Our AI Timing Score for NYXH is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NYXH belong to?
NYXOAH is classified under the Healthcare >> Medical Instruments & Supplies sector on the NASDAQ exchange
NYXH AI Analysis Summary
Our AI summary for NYXH: NYXOAH (NASDAQ), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of 0.00, ROE of -239.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.40
Price
-0.01
(-0.71%)
Day Change
|
|
|---|
NYXH, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.40 |
| PBV / Sector |
3.92 / 3.37
|
| Earning Per Share | -0.85 |
| PE / Sector |
N/A / 44.25
|
| PEG or PE/Growth / Sector |
N/A / -1.35
|
| Average 1M Daily Value |
0.32 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:15 |
| Symbol | NYXH |
| Name | NYXOAH |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 100.07 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 141.10 / 16,159.14 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Rue Edouard Belin 12, Mont-Saint-Guibert, Belgium, 1435
Phone: 32 1 045 90 75
Website: https://www.nyxoah.com
Employees: 153
Description: Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Medical Instruments & SuppliesAnalysed on the same criteria, ordered by market cap
Google